The highly selective dopamine D R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents
- 1 November 2019
- journal article
- research article
- Published by Elsevier in Neuropharmacology
- Vol. 158, 107597
Abstract
No abstract availableKeywords
Funding Information
- National Institute on Drug Abuse
This publication has 53 references indexed in Scilit:
- Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016JAMA, 2018
- Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological DiseasesFrontiers in Neuroscience, 2016
- Direct Bidirectional μ-Opioid Control of Midbrain Dopamine NeuronsThe Journal of Neuroscience, 2014
- The effects of the dopamine D3 receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjectsInternational Journal of Neuropsychopharmacology, 2011
- YQA14: a novel dopamine D3receptor antagonist that inhibits cocaine self‐administration in rats and mice, but not in D3receptor‐knockout miceAddiction Biology, 2011
- Current perspectives on selective dopamine D3receptor antagonists as pharmacotherapeutics for addictions and related disordersAnnals of the New York Academy of Sciences, 2010
- The effects of two highly selective dopamine D3 receptor antagonists (SB-277011A and NGB-2904) on food self-administration in a rodent model of obesityPharmacology Biochemistry and Behavior, 2008
- 1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: A Series of Potent and Selective Dopamine D3Receptor AntagonistsJournal of Medicinal Chemistry, 2007
- Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in ratsPsychopharmacology, 2004
- Acute administration of the selective D3 receptor antagonist SB‐277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male ratsSynapse, 2003